CA3173515A1 - Compositions et methodes pour reduire l'infectivite d'un virus - Google Patents

Compositions et methodes pour reduire l'infectivite d'un virus Download PDF

Info

Publication number
CA3173515A1
CA3173515A1 CA3173515A CA3173515A CA3173515A1 CA 3173515 A1 CA3173515 A1 CA 3173515A1 CA 3173515 A CA3173515 A CA 3173515A CA 3173515 A CA3173515 A CA 3173515A CA 3173515 A1 CA3173515 A1 CA 3173515A1
Authority
CA
Canada
Prior art keywords
pharmaceutical composition
composition
aerosol
inhibitor
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3173515A
Other languages
English (en)
Inventor
Steven C. Quay
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Atossa Therapeutics Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA3173515A1 publication Critical patent/CA3173515A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des compositions, des dispositifs et des méthodes de traitement d'une infection virale qui peuvent comprendre l'utilisation d'un inhibiteur d'enzyme, par exemple un inhibiteur de protéase. Une composition selon la présente divulgation peut comprendre un inhibiteur enzymatique à double action qui inhibe au moins deux enzymes et réduit l'infectivité d'un virus pour une cellule hôte. Des constituants supplémentaires peuvent comprendre un bioadhésif qui perturbe les enveloppes virales. Une méthode de traitement d'une infection virale peut comprendre l'administration d'un inhibiteur enzymatique, tel qu'un inhibiteur enzymatique à double action, à un sujet, et la réduction de l'infectivité du virus pour une cellule hôte du sujet. Les compositions peuvent être administrées par l'intermédiaire d'une administration nasale pour réduire l'infectivité d'une infection virale, par exemple une infection à coronavirus.
CA3173515A 2020-04-16 2021-04-15 Compositions et methodes pour reduire l'infectivite d'un virus Pending CA3173515A1 (fr)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US202063011291P 2020-04-16 2020-04-16
US63/011,291 2020-04-16
US202063012818P 2020-04-20 2020-04-20
US63/012,818 2020-04-20
US202063015370P 2020-04-24 2020-04-24
US63/015,370 2020-04-24
US202063032435P 2020-05-29 2020-05-29
US63/032,435 2020-05-29
US202063051800P 2020-07-14 2020-07-14
US63/051,800 2020-07-14
US202063112112P 2020-11-10 2020-11-10
US63/112,112 2020-11-10
PCT/US2021/027438 WO2021211808A1 (fr) 2020-04-16 2021-04-15 Compositions et méthodes pour réduire l'infectivité d'un virus

Publications (1)

Publication Number Publication Date
CA3173515A1 true CA3173515A1 (fr) 2021-10-21

Family

ID=78083678

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3173515A Pending CA3173515A1 (fr) 2020-04-16 2021-04-15 Compositions et methodes pour reduire l'infectivite d'un virus

Country Status (4)

Country Link
EP (1) EP4135660A1 (fr)
AU (1) AU2021254780A1 (fr)
CA (1) CA3173515A1 (fr)
WO (1) WO2021211808A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230390219A1 (en) * 2020-10-15 2023-12-07 Bausch + Lomb Ireland Limited Benzalkonium chloride foruse in treating conjunctivitis and/or covid-19
WO2023137404A1 (fr) * 2022-01-12 2023-07-20 University Of Virginia Patent Foundation Clivage du spicule par la furine comme stratégie de ciblage du sars-cov-2 pour rompre la chaîne du cycle d'infection
WO2023220712A1 (fr) * 2022-05-13 2023-11-16 The Trustees Of Columbia University In The City Of New York Protéases hôtes essentielles pour la propagation de parainfluenza dans le poumon humain : cibles potentielles pour interventions antivirales

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2593695A (en) * 1994-05-20 1995-12-18 Novavax, Inc. Antibacterial oil-in-water emulsions
IL122892A0 (en) * 1998-01-11 1998-08-16 Yeda Res & Dev Pharmaceutical compositions comprising a thiocarbamate
AU4841799A (en) * 1998-06-29 2000-01-17 Nastech Pharmaceutical Company, Inc Methods and pharmaceutical formulations for preventing and treating motion sickness
US7264932B2 (en) * 1999-09-24 2007-09-04 Applera Corporation Nuclease inhibitor cocktail
AU778498B2 (en) * 1999-10-22 2004-12-09 Lif-Hlaup Ehf. Bio-Gels Pharmaceuticals Inc. Pharmaceutical composition for treatment of mucosal epithelial ulceration and/or erosion
JP5651186B2 (ja) * 2009-10-30 2015-01-07 バイオジェニック イノベーションズ， リミテッド ライアビリティ カンパニー 薬剤耐性微生物を処置するためのメチルスルホニルメタン（ｍｓｍ）
IN2014MN02245A (fr) * 2012-04-10 2015-10-09 Rubicon Res Private Ltd
EP2666463A1 (fr) * 2012-05-21 2013-11-27 Synthon BV Composition liquide stabilisée comprenant du pemetrexed

Also Published As

Publication number Publication date
AU2021254780A1 (en) 2022-10-20
EP4135660A1 (fr) 2023-02-22
WO2021211808A1 (fr) 2021-10-21

Similar Documents

Publication Publication Date Title
CA3173515A1 (fr) Compositions et methodes pour reduire l'infectivite d'un virus
US20230110614A1 (en) Heparin and n-acetylcysteine for the treatment of a respiratory virus
AU2004312043B2 (en) Intranasal administration of glucose-regulating peptides
US20060069021A1 (en) Compositions and methods for intranasal administration of inactive analogs of PTH or inactivated preparations of PTH or PTH analogs
US20090325860A1 (en) Compositions for intranasal delivery of human insulin and uses thereof
EP1951198B1 (fr) Administration intranasale d'insuline a action rapide
US20060074025A1 (en) Therapeutic formulations for transmucosal administration that increase glucagon-like peptide-1 bioavailability
US20060210614A1 (en) Method of treatment of a metabolic disease using intranasal administration of exendin peptide
US20080318861A1 (en) Mucosal Delivery of Stabilized Formulations of Exendin
US20070161563A1 (en) A device for enhanced epithelial permeation of y2 receptor-binding peptides
BRPI0620586A2 (pt) formulação farmacêutica aquosa para administração intranasal e uso de uma formulação farmacêutica aquosa para elaborar um medicamento
US20070077283A1 (en) Method of enhancing transmucosal delivery of therapeutic compounds
WO2007061434A2 (fr) Formulation pharmaceutique de glp-1 et son utilisation pour traiter un syndrome metabolique
WO2007146448A1 (fr) Formulations pharmaceutiques de dérivés glp-1
MXPA06014215A (es) Formulaciones intranasales de interferon beta libres de estabilizadores que son proteinas o polipeptidos.
US20070185035A1 (en) Enhanced mucosal administration of neuroprotective peptides
WO2024026042A1 (fr) Compositions d'héparine pour le traitement d'une lésion pulmonaire et leurs procédés d'utilisation
MX2008004980A (es) Administracion intranasal de insulina de rapida accion
MXPA06009331A (es) Composiciones y metodos para mejorar el suministro mucosal de peptidos que se unen al receptor y2 y metodos para tratar y prevenir la obesidad

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220926

EEER Examination request

Effective date: 20220926

EEER Examination request

Effective date: 20220926